載入中
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
前收盤價
US$8.40
+US$0.14 · +1.69%
盤中時間採用ET。市場資料可能有所延遲。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日內區間
目前US$8.40
52週區間
目前US$8.40
盤中時間採用ET。市場資料可能有所延遲。
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
日內區間
目前US$8.40
52週區間
目前US$8.40
| 項目（USD） | 2025會計年度 |
|---|---|
| 營收 | 1861.8萬 USD |
| 毛利 | 1861.8萬 USD |
| 研究與開發 | 5375.6萬 USD |
| 銷售、一般及管理費用 | 4167.6萬 USD |
| 營業費用 | 9543.2萬 USD |
| 折舊和攤銷 | 32.3萬 USD |
| 營業利益 | −7681.4萬 USD |
| 淨利 | −7668.4萬 USD |
公司資料更新於 2026年10月12日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$25.00
上漲空間 197.62%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI690.53萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM318.49萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF251.25萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO109.95萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Russell 2000 Growth ETFIWO81.04萬0.01%139.17億 USD0.24%US$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA71.3萬0.00%218.24億 USD0.03%US$32.79+0.40%
iShares Micro-Cap ETFIWC38.72萬0.03%13.17億 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM17萬0.14%1.17億 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
